32.03

3.58% -1.19

Ultragenyx Pharmaceutical Inc (RARE)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché RARE Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$33.22

Aprire:

$33.36

Volume 24 ore:

1.07M

Relative Volume:

0.50

Capitalizzazione di mercato:

$3.15B

Reddito:

$669.43M

Utile/perdita netta:

$-609.36M

Rapporto P/E:

-5.2456

EPS:

-6.1061

Flusso di cassa netto:

$-507.20M

1 W Prestazione:

-10.71%

1M Prestazione:

+31.54%

6M Prestazione:

+33.07%

1 anno Prestazione:

+9.58%

Intervallo 1D:

$31.91

$33.58

Intervallo di 1 settimana:

$31.81

$35.79

Portata 52W:

$18.29

$39.89

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Nome

Ultragenyx Pharmaceutical Inc

Settore

Healthcare (1092)

Industria

Biotechnology (614)

Telefono

415-483-8800

Indirizzo

60 LEVERONI COURT, NOVATO, CA

Dipendente

1,371

Cinguettio

Prossima data di guadagno

2026-08-04

Ultimi documenti SEC

RARE's Discussions on Twitter

Compare RARE vs VRTX, REGN, ARGX, RVMD, ALNY

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
RARE Ultragenyx Pharmaceutical Inc	32.03	3.27B	669.43M	-609.36M	-507.20M	-6.1061
VRTX Vertex Pharmaceuticals Inc	476.31	121.89B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.12	69.52B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	859.43	54.49B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	184.97	39.11B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	281.26	38.46B	4.29B	577.22M	641.34M	4.2086

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-24	Downgrade	Goldman	Buy → Neutral
2025-10-20	Iniziato	Wells Fargo	Overweight
2025-07-28	Ripresa	H.C. Wainwright	Buy
2025-05-28	Iniziato	William Blair	Outperform
2024-06-06	Aggiornamento	Goldman	Neutral → Buy
2024-04-22	Iniziato	RBC Capital Mkts	Outperform
2023-12-08	Iniziato	Wells Fargo	Overweight
2023-06-14	Ripresa	Credit Suisse	Outperform
2023-06-06	Aggiornamento	Evercore ISI	In-line → Outperform
2023-04-26	Iniziato	Cantor Fitzgerald	Overweight
2023-01-18	Ripresa	Canaccord Genuity	Buy
2022-12-30	Ripresa	H.C. Wainwright	Buy
2022-11-03	Aggiornamento	Robert W. Baird	Neutral → Outperform
2022-10-13	Aggiornamento	Guggenheim	Neutral → Buy
2022-08-01	Downgrade	Evercore ISI	Outperform → In-line
2022-03-16	Aggiornamento	Credit Suisse	Neutral → Outperform
2022-02-11	Aggiornamento	JP Morgan	Neutral → Overweight
2021-09-30	Iniziato	H.C. Wainwright	Buy
2021-08-19	Iniziato	UBS	Sell
2021-07-15	Iniziato	Guggenheim	Neutral
2021-06-29	Aggiornamento	BofA Securities	Neutral → Buy
2021-06-04	Ripresa	Robert W. Baird	Neutral
2021-05-06	Aggiornamento	Citigroup	Neutral → Buy
2021-05-06	Aggiornamento	Evercore ISI	In-line → Outperform
2021-04-26	Ripresa	Credit Suisse	Neutral
2021-03-02	Ripresa	Stifel	Buy
2021-02-12	Downgrade	JP Morgan	Overweight → Neutral
2020-12-07	Downgrade	Wedbush	Outperform → Neutral
2020-11-24	Ripresa	Evercore ISI	In-line
2020-11-12	Downgrade	BofA Securities	Buy → Neutral
2019-08-02	Ripresa	Wedbush	Outperform
2019-03-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2019-02-22	Ripresa	Raymond James	Outperform
2019-01-02	Downgrade	Raymond James	Outperform → Mkt Perform
2018-11-08	Aggiornamento	Citigroup	Sell → Neutral
2018-09-10	Iniziato	Morgan Stanley	Equal-Weight
2018-06-21	Downgrade	Credit Suisse	Outperform → Neutral
2018-05-11	Aggiornamento	Barclays	Equal Weight → Overweight
2018-05-10	Iniziato	Goldman	Neutral
2018-04-18	Aggiornamento	SunTrust	Hold → Buy
2018-03-22	Ripresa	Piper Jaffray	Overweight
2018-02-21	Reiterato	Stifel	Buy
2018-01-22	Aggiornamento	Evercore ISI	In-line → Outperform
2018-01-18	Iniziato	Credit Suisse	Outperform
2017-12-05	Reiterato	Barclays	Equal Weight
2017-12-04	Aggiornamento	Jefferies	Hold → Buy
2017-09-14	Aggiornamento	Wedbush	Neutral → Outperform

Mostra tutto

Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie

Jul 13, 2026

Wedbush Raises Price Target on Ultragenyx Pharmaceutical to $30 From $26, Keeps Neutral Rating - Moomoo

Jul 13, 2026

Jul 10, 2026

RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits

Jul 10, 2026

Jul 09, 2026

Ultragenyx Pharmaceutical (RARE) Is Up 7.4% After Index Migration To Russell 2000 And Value BenchmarksHas The Bull Case Changed? - Sahm

Jul 09, 2026

(RARE) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Jul 09, 2026

Jul 08, 2026

Ultragenyx releases 2025 impact report on rare disease work By Investing.com - Investing.com South Africa

Jul 08, 2026

Ultragenyx releases 2025 impact report on rare disease work - Investing.com

Jul 08, 2026

Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact - The Manila Times

Jul 08, 2026

Ultragenyx Releases 2025 Impact Report Highlighting Progress in Rare Disease Therapies, Patient Access and Sustainability - Quiver Quantitative

Jul 08, 2026

Ultragenyx Releases 2025 Impact Report Emphasizing - GlobeNewswire

Jul 08, 2026

Ultragenyx says five rare-disease programs reached pivotal trials in 2025 - Stock Titan

Jul 08, 2026

Jul 07, 2026

RBC Capital Adjusts Ultragenyx Pharmaceutical Price Target to $40 From $35, Maintains Outperform Rating - Moomoo

Jul 07, 2026

RBC Capital Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Raises Target Price to $40 - Moomoo

Jul 07, 2026

Jul 06, 2026

Ultragenyx CFO Howard Horn sells $155,644 in company shares By Investing.com - Investing.com South Africa

Jul 06, 2026

Form 144 ULTRAGENYX PHARMACEUTICAL INC. For: 1 July By Investing.com - Investing.com Canada

Jul 01, 2026

RARE (NASDAQ: RARE) affiliate reports insider sales and scheduled awards - Stock Titan

Jul 01, 2026

Jun 30, 2026

RARE DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ultrage - The National Law Review

Jun 30, 2026